PET-based lesion graphs meet clinical data: An interpretable cross-attention framework for DLBCL treatment response prediction.

in Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society by Oriane Thiery, Mira Rizkallah, Clément Bailly, Caroline Bodet-Milin, Emmanuel Itti, René-Olivier Casasnovas, Steven Le Gouill, Thomas Carlier, Diana Mateus

TLDR

  • The study proposes a graph neural network-based framework for integrating FDG-PET/CT images and clinical data to predict 2-year progression-free survival (PFS) for DLBCL patients.
  • The framework effectively fuses multi-lesion image information with clinical indicators to improve diagnostic accuracy.

Abstract

Diffuse Large B-cell Lymphoma (DLBCL) is a lymphatic cancer of steadily growing incidence. Its diagnostic and follow-up rely on the analysis of clinical biomarkers and 18F-Fluorodeoxyglucose (FDG)-PET/CT images. In this context, we target the problem of assisting in the early identification of high-risk DLBCL patients from both images and tabular clinical data. We propose a solution based on a graph neural network model, capable of simultaneously modeling the variable number of lesions across patients, and fusing information from both data modalities and over lesions. Given the distributed nature of DLBCL lesions, we represent the PET image of each patient as an attributed lesion graph. Such lesion-graphs keep all relevant image information while offering a compact tradeoff between the characterization of full images and single lesions. We also design a cross-attention module to fuse the image attributes with clinical indicators, which is particularly challenging given the large difference in dimensionality and prognostic strength of each modality. To this end, we propose several cross-attention configurations, discuss the implications of each design, and experimentally compare their performances. The last module fuses the updated attributes across lesions and makes a probabilistic prediction of the patient's 2-year progression-free survival (PFS). We carry out the experimental validation of our proposed framework on a prospective multicentric dataset of 545 patients. Experimental results show our framework effectively integrates the multi-lesion image information improving over a model relying only on the most prognostic clinical data. The analysis further shows the interpretable properties inherent to our graph-based design, which enables tracing the decision back to the most important lesions and features.

Overview

  • The study focuses on developing a system to aid in the early identification of high-risk DLBCL patients by analyzing both FDG-PET/CT images and clinical data.
  • The proposed system uses a graph neural network model that can simultaneously process multiple lesions across patients and fuse information from both data modalities and lesions.
  • The primary objective is to predict a patient's 2-year progression-free survival (PFS) from a combination of clinical indicators and graph-structured image features.

Comparative Analysis & Findings

  • The experimental results show that the proposed framework effectively integrates multi-lesion image information to improve over a model relying only on the most prognostic clinical data.
  • The analysis highlights the interpretable properties inherent to the graph-based design, enabling the tracing of decisions back to the most important lesions and features.
  • The results demonstrate the potential of the proposed framework to support early identification of high-risk DLBCL patients and improve treatment outcomes.

Implications and Future Directions

  • The study's findings could lead to the development of more effective diagnostic and treatment strategies for DLBCL patients.
  • Future research should focus on validating the framework on larger, more diverse datasets and exploring additional data modalities, such as genomic or protein expression data.
  • The use of graph neural networks in medical image analysis has potential applications in other domains, such as precision medicine and personalized treatment planning.